![](/wp-content/uploads/2024/05/Screenshot-2024-05-08-at-6.13.45%E2%80%AFPM.png)
$599
BI Partners with Walgreens for Clinical Trial Enrollment; Cytokinetics Initiates Pediatric Aficamten oHCM Study
Two cardiometabolic-related news items have been observed: Boehringer Ingelheim announced a partnership with Walgreens for clinical trials, including obesity (view press release); and Cytokinetics announced the initiation of pediatric aficamten oHCM study, CEDAR-HCM (view press release). Below, FENIX provides highlights and insights for the respective news items.